Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES DOXAZOSIN MESYLATE TABLETS
Authorized Generic of Cardura®

PEAPACK, NJ, July 2014 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of Doxazosin Mesylate tablets to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 1 mg x 100; 2 mg x 100; 4 mg x 100 and 8 mg x 100.

Greenstone’s Doxazosin Mesylate Tablets product is the authorized generic of, and equivalent to the innovator’s product, CARDURA® (doxazosin mesylate). This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s largest pharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s Doxazosin Mesylate tablets at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.